Uncategorized

Could diet and gut health impact the lived experience of lupus? This intriguing question lies at the heart of a groundbreaking initiative by Lupus Therapeutics (LT), the clinical research affiliate of the Lupus Research Alliance (LRA), called IDEAL (Investigate Dietary Approaches for Lupus). IDEAL will provide up to two grants for pilot clinical studies evaluating … An IDEAL Initiative in Lupus Research: Q&A With Dr. Stacie J. Bell, Lupus Therapeutics, and Dr. Teodora Staeva, Lupus Research Alliance 

Lupus Therapeutics, the clinical research affiliate of the Lupus Research Alliance, is eager to share exciting news. The U.S. Food and Drug Administration accepted the supplemental Biologics License Application (sBLA) from Genentech for Gazyva® (obinutuzumab) as a potential treatment of lupus nephritis. The acceptance is based on results from the Phase 3 REGENCY study showing improved complete renal … FDA Accepts Application for Potential Treatment for Lupus Nephritis, Gazyva®

New ACR guidelines for advancing the management of lupus nephritis (LN). Novel approaches and promising data from early- to late-stage lupus treatments in development, including CAR T cell therapies. Strategies for promoting equity in lupus clinical trials. These were among the key presentations at ACR (American College of Rheumatology) Convergence 2024. Lupus Therapeutics (LT), the … LRA Spotlight on ACR Convergence 2024: Lupus Therapeutics-Supported Clinical Research and More

The American College of Rheumatology (ACR) released a summary of the 2024 ACR Guideline for the Screening, Treatment, and Management of Lupus Nephritis during ACR Convergence 2024. “This is the College’s first lupus nephritis guideline since 2012 and provides evidence-based, expert guidance for the condition in adults and children.” Lupus Therapeutics, clinical affiliate of the Lupus … ACR Released a Summary of the 2024 ACR Guideline for the Screening, Treatment, and Management of Lupus Nephritis

The Lupus Research Alliance (LRA) and clinical research affiliate Lupus Therapeutics (LT) are excited to share positive news of the Phase 3 REGENCY clinical trial showing benefits of Gazyva® (obinutuzumab) in treating people with active lupus nephritis (inflammation of the kidney associated with lupus). In development as a potential treatment for lupus nephritis, Gazyva is approved in … Gazyva® Shows Positive Results in Phase 3 Lupus Nephritis Trial

Lupus Therapeutics, the clinical research affiliate of the Lupus Research Alliance, is proud to share positive topline results from the Phase 3 PHOENYCS GO study evaluating the investigational therapy dapirolizumab pegol in people living with moderate-to-severe systemic lupus. Results of the Phase 3 PHOENYCS GO study were reported by study sponsors UCB and Biogen. The … Investigational Treatment Dapirolizumab Pegol Shows Positive Results in Phase 3 Clinical Trial

A study recently published in Lupus Science and Medicine showed that krill oil concentrate helped to increase Omega-3 deficiency in people living with lupus. Secondary findings on a small subset of people with more severe lupus in the ORKIDS study suggest that krill oil concentrate may impact disease activity, but further study is warranted. Lupus … Statement in Response to Recent Lupus Science and Medicine Publication